Over the past 12‑18 months, the Nasal Care Spray industry trends have accelerated through a blend of strategic alliances, M&A activity, and innovative product roll‑outs. In Q2 2025, AllergyTech partnered with PharmaGen to co‑develop a digitally‑enabled, preservative‑free spray that syncs with mobile health apps, targeting tech‑savvy consumers. Meanwhile, Vaxine Bio acquired NasoClear Ltd., expanding its pipeline with a patented muco‑adhesive formulation aimed at chronic rhinitis patients. The FDA’s March 2025 guidance on over‑the‑counter nasal devices streamlined labeling requirements, prompting several firms to relaunch legacy brands with updated dosage indicators. Consumer demand shifted toward “clean label” and rapid‑relief options, driving a 22 % YoY rise in sales of botanical‑based sprays. In the funding arena, Respira Ventures closed a $45 million Series C round to scale its nanotech spray platform across Europe and Asia, earmarking $12 million for new manufacturing facilities. Enterprise customers, particularly large pharmacy chains, are integrating nasal spray dispensers into their in‑store wellness kiosks, boosting B2B volume and creating new data‑driven replenishment models. Collectively, these moves position the market for double‑digit growth through 2028.